Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

MBRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.10%

Insider Buying (Last 12 Months): $159,990.30

Insider Selling (Last 12 Months): $0.00

Moleculin Biotech Insider Trading History Chart

Moleculin Biotech Share Price & Price History

^$2.73

▼ -0.1 (-3.53%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

#1 Crypto of 2024

From True Market Insiders | Ad

Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…

#1 FREE Crypto for 2024

Moleculin Biotech Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/26/2023	Jonathan P Foster	CFO	Buy	1,932	$10.35	$19,996.20	5,370
12/26/2023	Robert E George	Director	Buy	966	$10.35	$9,998.10	977
12/26/2023	Walter V Klemp	CEO	Buy	12,560	$10.35	$129,996.00	45,392
11/25/2022	Walter V Klemp	CEO	Buy	3,000	$19.20	$57,600.00	27,326
11/21/2022	Walter V Klemp	CEO	Buy	1,500	$17.25	$25,875.00	24,326
11/16/2022	Walter V Klemp	CEO	Buy	5,680	$14.55	$82,644.00	21,176

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

SEC Filings (Institutional Ownership Changes) for Moleculin Biotech (NASDAQ:MBRX)

15.52% of Moleculin Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Moleculin Biotech Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2024	Armistice Capital LLC	156,000	$0.55M	0.0%	+5.1%	6.747%
2/13/2024	Armistice Capital LLC	3,207,417	$2.75M	0.0%	N/A	9.600%
1/17/2024	Atticus Wealth Management LLC	50,001	$43K	0.0%	N/A	0.168%
5/15/2023	Sio Capital Management LLC	1,010,956	$0.97M	0.5%	-2.5%	3.407%
7/25/2022	Walker Asset Management LLC	20,708	$32K	0.0%	N/A	0.072%
4/20/2022	Sigma Planning Corp	57,500	$0.10M	0.0%	+33.7%	0.201%
2/2/2022	Sigma Planning Corp	43,000	$80K	0.0%	N/A	0.150%
11/9/2021	BlackRock Inc.	270,402	$0.81M	0.0%	-2.5%	0.947%
9/17/2021	Virtu Financial LLC	25,302	$93K	0.0%	N/A	0.089%
8/16/2021	Occudo Quantitative Strategies LP	29,188	$0.11M	0.0%	+31.7%	0.102%
8/16/2021	State Street Corp	59,900	$0.22M	0.0%	N/A	0.210%
8/13/2021	Geode Capital Management LLC	237,586	$0.87M	0.0%	+35.9%	0.835%
8/13/2021	Vanguard Group Inc.	1,047,529	$3.84M	0.0%	+123.6%	3.683%
8/12/2021	XTX Topco Ltd	32,997	$0.12M	0.0%	N/A	0.116%
8/5/2021	GSA Capital Partners LLP	31,120	$0.11M	0.0%	N/A	0.109%
5/21/2021	Citadel Advisors LLC	13,843	$56K	0.0%	N/A	0.049%
5/19/2021	Squarepoint Ops LLC	28,904	$0.12M	0.0%	+134.2%	0.102%
5/18/2021	Cubist Systematic Strategies LLC	26,624	$0.11M	0.0%	N/A	0.094%
5/18/2021	Citadel Advisors LLC	13,843	$56K	0.0%	N/A	0.049%
5/14/2021	Occudo Quantitative Strategies LP	22,158	$90K	0.0%	N/A	0.078%
5/12/2021	Northern Trust Corp	50,731	$0.21M	0.0%	-43.1%	0.178%
5/12/2021	Geode Capital Management LLC	174,822	$0.71M	0.0%	-40.6%	0.615%
5/7/2021	BlackRock Inc.	239,326	$0.98M	0.0%	+449.7%	0.841%
4/27/2021	Harel Insurance Investments & Financial Services Ltd.	10,000	$0.14M	0.0%	N/A	0.035%
4/14/2021	Taylor Cottrill Erickson & Associates Inc.	16,964	$69K	0.0%	-83.3%	0.060%
2/10/2021	Renaissance Technologies LLC	948,503	$0.76M	0.0%	+6.4%	7.901%
11/13/2020	Truist Financial Corp	175,000	$0.14M	0.0%	+25.0%	0.284%

Data available starting January 2016

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Today's Range

Now: $2.73

$2.70

$2.93

50 Day Range

MA: $2.55

$2.33

$3.09

52 Week Range

Now: $2.73

$2.12

$15.75

Volume

31,127 shs

Average Volume

60,597 shs

Market Capitalization

$8.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Who are the company insiders with the largest holdings of Moleculin Biotech?: Moleculin Biotech's top insider investors include:
Walter V Klemp (CEO)
Jonathan P Foster (CFO)
Robert E George (Director)
Learn More about top insider investors at Moleculin Biotech.

First JFK… next Elon?